Regeneron
Stories
-
Sanofi posts results of Phase 3 Itepekimab trial in COPD
The study, NCT04751487 (AERIFY-2), enrolled 1234 participants and completed in April 2025. It evaluated itepekimab versus placebo on exacerbation rates, pulmonary function, and safety in moderate-to-severe COPD patients.